Further work is required to determine when STING should be inhibited to block its tumour-promoting effects, such as driving CIN+ cancer cell survival and metastasis [130], or activated to stimulate its tumour-suppressive effects, including immune clearance of cancer cells [131]. The gene discussed is STING1; the disease is cancer.